Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Iteos Therapeutics Inc (ITOS)

Iteos Therapeutics Inc (ITOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 848,464
  • Shares Outstanding, K 35,104
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,030 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.68
Trade ITOS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate 0.12
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.42 +2.60%
on 07/27/21
26.35 -8.80%
on 07/09/21
-1.62 (-6.32%)
since 06/30/21
3-Month
17.43 +37.87%
on 06/04/21
29.76 -19.27%
on 06/14/21
+0.52 (+2.21%)
since 04/30/21
52-Week
17.43 +37.87%
on 06/04/21
47.61 -49.53%
on 03/03/21
+5.53 (+29.89%)
since 07/30/20

Most Recent Stories

More News
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes....

GSK : 40.14 (+0.10%)
BAYRY : 14.8550 (-1.82%)
ALEC : 24.03 (-0.15%)
ITOS : 24.03 (-0.58%)
Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

REGN : 574.61 (-1.46%)
GSK : 40.14 (+0.10%)
BIIB : 326.73 (-0.74%)
VRTX : 201.58 (+0.60%)
NVAX : 179.33 (-2.54%)
SAGE : 43.73 (-0.91%)
ITOS : 24.03 (-0.58%)
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

GSK : 40.14 (+0.10%)
RHHBY : 48.2600 (+1.05%)
MRK : 76.87 (-0.08%)
ITOS : 24.03 (-0.58%)
iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for...

JPM : 151.78 (-0.80%)
ITOS : 24.03 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery and development of immuno-oncology therapeutics. iTeos Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 24.96
2nd Resistance Point 24.70
1st Resistance Point 24.37
Last Price 24.03
1st Support Level 23.78
2nd Support Level 23.52
3rd Support Level 23.19

See More

52-Week High 47.61
Fibonacci 61.8% 36.08
Fibonacci 50% 32.52
Fibonacci 38.2% 28.96
Last Price 24.03
52-Week Low 17.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar